Cargando…

Use of Next-Generation Sequencing for the Molecular Diagnosis of 1,102 Patients With a Autosomal Optic Neuropathy

Advances in next-generation sequencing (NGS) facilitate the diagnosis of genetic disorders. To evaluate its use for the molecular diagnosis of inherited optic neuropathy (ION), a blinding disease caused by the degeneration of retinal ganglion cells, we performed genetic analysis using targeted NGS o...

Descripción completa

Detalles Bibliográficos
Autores principales: Charif, Majida, Bris, Céline, Goudenège, David, Desquiret-Dumas, Valérie, Colin, Estelle, Ziegler, Alban, Procaccio, Vincent, Reynier, Pascal, Bonneau, Dominique, Lenaers, Guy, Amati-Bonneau, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027346/
https://www.ncbi.nlm.nih.gov/pubmed/33841295
http://dx.doi.org/10.3389/fneur.2021.602979
_version_ 1783675799089446912
author Charif, Majida
Bris, Céline
Goudenège, David
Desquiret-Dumas, Valérie
Colin, Estelle
Ziegler, Alban
Procaccio, Vincent
Reynier, Pascal
Bonneau, Dominique
Lenaers, Guy
Amati-Bonneau, Patrizia
author_facet Charif, Majida
Bris, Céline
Goudenège, David
Desquiret-Dumas, Valérie
Colin, Estelle
Ziegler, Alban
Procaccio, Vincent
Reynier, Pascal
Bonneau, Dominique
Lenaers, Guy
Amati-Bonneau, Patrizia
author_sort Charif, Majida
collection PubMed
description Advances in next-generation sequencing (NGS) facilitate the diagnosis of genetic disorders. To evaluate its use for the molecular diagnosis of inherited optic neuropathy (ION), a blinding disease caused by the degeneration of retinal ganglion cells, we performed genetic analysis using targeted NGS of 22 already known and candidate genes in a cohort of 1,102 affected individuals. The panel design, library preparation, and sequencing reactions were performed using the Ion AmpliSeq technology. Pathogenic variants were detected in 16 genes in 245 patients (22%), including 186 (17%) and 59 (5%) dominant and recessive cases, respectively. Results confirmed that OPA1 variants are responsible for the majority of dominant IONs, whereas ACO2 and WFS1 variants are also frequently involved in both dominant and recessive forms of ION. All pathogenic variants were found in genes encoding proteins involved in the mitochondrial function, highlighting the importance of mitochondria in the survival of retinal ganglion cells.
format Online
Article
Text
id pubmed-8027346
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80273462021-04-09 Use of Next-Generation Sequencing for the Molecular Diagnosis of 1,102 Patients With a Autosomal Optic Neuropathy Charif, Majida Bris, Céline Goudenège, David Desquiret-Dumas, Valérie Colin, Estelle Ziegler, Alban Procaccio, Vincent Reynier, Pascal Bonneau, Dominique Lenaers, Guy Amati-Bonneau, Patrizia Front Neurol Neurology Advances in next-generation sequencing (NGS) facilitate the diagnosis of genetic disorders. To evaluate its use for the molecular diagnosis of inherited optic neuropathy (ION), a blinding disease caused by the degeneration of retinal ganglion cells, we performed genetic analysis using targeted NGS of 22 already known and candidate genes in a cohort of 1,102 affected individuals. The panel design, library preparation, and sequencing reactions were performed using the Ion AmpliSeq technology. Pathogenic variants were detected in 16 genes in 245 patients (22%), including 186 (17%) and 59 (5%) dominant and recessive cases, respectively. Results confirmed that OPA1 variants are responsible for the majority of dominant IONs, whereas ACO2 and WFS1 variants are also frequently involved in both dominant and recessive forms of ION. All pathogenic variants were found in genes encoding proteins involved in the mitochondrial function, highlighting the importance of mitochondria in the survival of retinal ganglion cells. Frontiers Media S.A. 2021-03-25 /pmc/articles/PMC8027346/ /pubmed/33841295 http://dx.doi.org/10.3389/fneur.2021.602979 Text en Copyright © 2021 Charif, Bris, Goudenège, Desquiret-Dumas, Colin, Ziegler, Procaccio, Reynier, Bonneau, Lenaers and Amati-Bonneau. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Charif, Majida
Bris, Céline
Goudenège, David
Desquiret-Dumas, Valérie
Colin, Estelle
Ziegler, Alban
Procaccio, Vincent
Reynier, Pascal
Bonneau, Dominique
Lenaers, Guy
Amati-Bonneau, Patrizia
Use of Next-Generation Sequencing for the Molecular Diagnosis of 1,102 Patients With a Autosomal Optic Neuropathy
title Use of Next-Generation Sequencing for the Molecular Diagnosis of 1,102 Patients With a Autosomal Optic Neuropathy
title_full Use of Next-Generation Sequencing for the Molecular Diagnosis of 1,102 Patients With a Autosomal Optic Neuropathy
title_fullStr Use of Next-Generation Sequencing for the Molecular Diagnosis of 1,102 Patients With a Autosomal Optic Neuropathy
title_full_unstemmed Use of Next-Generation Sequencing for the Molecular Diagnosis of 1,102 Patients With a Autosomal Optic Neuropathy
title_short Use of Next-Generation Sequencing for the Molecular Diagnosis of 1,102 Patients With a Autosomal Optic Neuropathy
title_sort use of next-generation sequencing for the molecular diagnosis of 1,102 patients with a autosomal optic neuropathy
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027346/
https://www.ncbi.nlm.nih.gov/pubmed/33841295
http://dx.doi.org/10.3389/fneur.2021.602979
work_keys_str_mv AT charifmajida useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT brisceline useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT goudenegedavid useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT desquiretdumasvalerie useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT colinestelle useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT ziegleralban useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT procacciovincent useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT reynierpascal useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT bonneaudominique useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT lenaersguy useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy
AT amatibonneaupatrizia useofnextgenerationsequencingforthemoleculardiagnosisof1102patientswithaautosomalopticneuropathy